52
Participants
Start Date
May 7, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
April 30, 2026
TQ05105 tablets
Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
NOT_YET_RECRUITING
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Anhui Provincial Hospital, Hefei
NOT_YET_RECRUITING
Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin
RECRUITING
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
The Affiliated People's Hospital of Ningbo University, Ningbo
NOT_YET_RECRUITING
Xiangyang Central Hospital, Xiangyang
NOT_YET_RECRUITING
Guangzhou First People's Hospital, Guangzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Guangxi Medical University, Nanning
NOT_YET_RECRUITING
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an
NOT_YET_RECRUITING
The 940th hospital of joint logistics support force of Chinese people's liberation army, Lanzhou
NOT_YET_RECRUITING
The Second Hospital of Hebei Medical University, Shijiazhuang
NOT_YET_RECRUITING
Tai'an Central Hospital, Taian
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY